What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?

Nephrology

Volumn 9, Issue 4, 2004, Pages 223-228

  Roger, Simon D ^a   Cooper, Bruce ^a  

^a GOSFORD HOSPITAL   (Australia)

Author keywords

Anaemia; Chronic kidney disease; Darbepoetin alfa; Epoetin alfa

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD ANALYSIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UREMIA; VASCULAR DISEASE;

ANEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RENAL DIALYSIS; UREMIA;

EID: 4844228123     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2004.00261.x     Document Type: Article

References (25)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. lancet 1986; 2: 1175-8.
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987; 316: 73-8.
3. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. J. Med. 1989; 321: 158-63.
4. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br. J. Cancer 2001; 84: 3-10.
5. Macdougall IC. Once-weekly erythropoietic therapy: Is there a difference between the available preparations? Nephrol. Dial. Transplant. 2002; 17: 2047-51.
6. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001; 60: 741-7.
7. Department of Health and Aging, Australian Government. The 2002-03 highly specialised drugs programme national expenditure report. Retrieved 06 November, 2003, from http://www.health.gov.au/pbs/pharm/stats/natexprpt
8. Lui SF, Law CB, Ting SM, Li P, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin. Nephrol. 1991; 36: 246-51.
9. Lui SF, Wong KC, Li PK, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients. Am. J. Nephrol. 1992; 12: 55-60.
10. Anonymous. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients. Nephron 1992; 61: 399-403.
11. Lago M, Perez-Garcia R, Garcia de Vinuesa MS, Anaya F, Valderrabano F. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients. Nephron 1996; 72: 723-4.
12. Aljama P, Bommer J, Canaud B et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol. Dial. Transplant. 2001; 16: 22-8.
13. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol. Dial. Transplant. 2003; 18: 362-9.
14. Vanrenterghem Y, Barany P, Mann JF et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62: 2167-75.
15. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am. J. Nephrol. 2003; 23: 106-11.
16. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. 2002; 40: 110-18.
17. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: Recommendations from clinical studies. Pharmacotherapy 2002; 22: S160-5.
18. Jacobs C, Horl WH, Macdougall IC et al. European best practice guidelines 9-13: Anaemia management. Nephrol. Dial. Transplant. 2000; 15: 33-42.
19. Janssen Cilag Australia. Australian Survey of Anaemia Management (ASAM), 2003 (data on file).
20. Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF. Anemia management of adult hemodialysis patients in the US results: From the 1997 ESRD Core Indicators Project. Kidney Int. 2000; 57: 578-89.
21. Barnett AL, Cremieux PY. Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis. Pharmacotherapy 2003; 23: 690-3; discussion 693-4.
22. Glaspy JA, Jadeja JS, Justice G et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br. J. Cancer 2002; 87: 268-76.
23. Hedenus M, Hansen S, Taylor K et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br. J. Haematol. 2002; 119: 79-86.
24. Department of Health and Aging Australian Government. Schedule of pharmaceutical benefits, 2003. Retrieved 06 November, 2003, from www1.health.gov.au/pbs/scripts/dispsp100.cfm?startchart=D
25. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N. Engl. J. Med. 1998; 339: 578-83.